SciNeuro Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SciNeuro Pharmaceuticals - overview
Established
2020
Location
Rockville, MD, US
Primary Industry
Biotechnology
About
Established in 2020 and based in Rockville, US, Saishen (Shanghai) Pharmaceutical Technology Co. , Ltd. , trading as SciNeuro Pharmaceuticals, is a biopharmaceutical company focusing on the research and development of central nervous system drugs. The company is committed to internal innovation and global collaboration by building its CNS product portfolio.
In December 2025, SciNeuro Pharmaceuticals raised USD 53 million in Series B funding co-led by returning investors Lilly Asia Ventures and ARCH Venture Partners. The company mainly develops central nervous system drugs to treat neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD). Its R&D pipeline includes AD/Lp-PLA2, PD/alpha-synuclein, etc. The company generates revenue through research and development, production, and sales of new drugs for the central nervous system and other related products.
The Series B funding raised in December 2025 will be used to advance the clinical development of pipelines for Alzheimer's disease, Parkinson's disease, and other conditions, as well as for team building.
Current Investors
ARCH Venture Partners, Hong Shan, General Atlantic
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.scineuro.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.